Clinical trial
Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
NCT02087111 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin
- Lead sponsor
- Queen Mary University of London
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 30, 2014
- Completion date
- November 1, 2016
- Enrollment
- 14 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.